Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

22 Jul 2019

Abstract excerpt

BACKGROUND: Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute myeloid leukemia (r/r AML), but identification of this subset remains difficult. METHODS: To search for biomarkers of response, we measured genome-wide DNA methylation, mutations of 54 genes, and expression of a panel of 7 genes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31331399
DOI: 10.1186/s13148-019-0704-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaPMID 31331399Read ↗

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 studySemantic proximity Read ↗

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaSemantic proximity Read ↗

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLSemantic proximity Read ↗

Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid LeukaemiaSemantic proximity Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity Read ↗

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaSemantic proximity Read ↗

Blood Based Biomarkers of DNA Methylation Associated with Platinum Resistance in High Grade Serous Ovarian CancerSemantic proximity Read ↗

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read ↗

Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell linesSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.